• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form POS AM filed by Asensus Surgical Inc.

    8/22/24 9:25:27 AM ET
    $ASXC
    Medical/Dental Instruments
    Health Care
    Get the next $ASXC alert in real time by email
    POS AM 1 asxc20240820c_posam.htm FORM POS AM asxc20240820c_posam.htm

     

    As filed with the Securities and Exchange Commission on August 22, 2024

     

    Registration No. 333-263711

    Registration No 333-224049

    Registration No 333-209486

    Registration No 333-209485

     


     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM S-3

    POST-EFFECTIVE AMENDMENT NO. 1 TO REGISTRATION STATEMENT NO. 333-263711

    POST-EFFECTIVE AMENDMENT NO. 1 TO REGISTRATION STATEMENT NO. 333-224049

    POST-EFFECTIVE AMENDMENT NO. 1 TO REGISTRATION STATEMENT NO. 333-209486

    POST-EFFECTIVE AMENDMENT NO. 1 TO REGISTRATION STATEMENT NO. 333-209485

    UNDER

    THE SECURITIES ACT OF 1933

     

    ASENSUS SURGICAL, INC.

    (Exact name of registrant as specified in its charter)

     

    Delaware

     

    11-2962080

    (State or other jurisdiction

    of incorporation or organization)

     

    (I.R.S. Employer

    Identification Number)

     

    1 TW Alexander Drive, Suite 160

    Durham, NC 27703

    (919) 765-8400

    (Address of principal executive offices and zip code)

     

    Shameze Rampertab

    Executive Vice President and Chief Financial Officer

    1 TW Alexander Drive, Suite 160

    Durham, NC 27703

    (919) 765-8400

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

     

    Copy to:

     

    Mary J. Mullany, Esquire

    Ballard Spahr LLP

    1735 Market Street, 51st Floor

    Philadelphia, PA 19103

    (215) 864-8631

     

    Approximate date of commencement of proposed sale to the public: Not Applicable.

     

    If the only securities being registered on this form are being offered pursuant to dividend or interest reinvestment plans, please check the following box. ☐

     

    If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box. ☐

     

    If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

     

     

     

     

    If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

     

    If this Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective on filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box. ☐

     

    If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box. ☐

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer

    ☐

    Accelerated filer

    ☐

           

    Non-accelerated filer

    ☒

    Smaller reporting company

    ☒

           
       

    Emerging growth company

    ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     

     

    TERMINATION OF REGISTRATION

     

    This Post-Effective Amendment relates to the following Registration Statements on Form S-3 (the “Registration Statements”) filed by Asensus Surgical, Inc. (the “Company”) with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), to deregister any and all securities registered but unsold or otherwise unissued as of the date hereof under the Registration Statements:

     

     

    •

    Form S-3, File No. 333-263711, filed on March 18, 2022 and declared effective on April 28, 2022, registering up to $150,000,000 in the aggregate of securities consisting of the Company’s common stock, preferred stock, warrants and units.

     

    •

    Form S-3/A, File No. 333-224049, filed on March 30, 2018 and declared effective on April 18, 2018, registering 2,531,195 shares of the Company’s common stock (not stock-split adjusted) for resale.

     

    •

    Form S-3/A, File No. 333-209486, filed on March 4, 2016 and declared effective on March 14, 2016, registering 15,543,413 shares of the Company’s common stock (not stock-split adjusted) for resale.

     

    •

    Form S-3/A, File No. 333-209485, filed on March 4, 2016 and declared effective on March 14, 2016 the same day, registering 42,759,127 shares of the Company’s common stock (not stock-split adjusted) for resale.

     

    Pursuant to the Agreement and Plan of Merger, dated as of June 6, 2024 (the “Merger Agreement”), by and among the Company, KARL STORZ Endoscopy-America, Inc., a California corporation (“Parent”), and Karl Storz California Inc., a California corporation and a wholly owned subsidiary of Parent (“Merger Sub”), Merger Sub merged with and into the Company, with the Company continuing as the surviving corporation and a direct wholly owned subsidiary of Parent.

     

    As a result of the transactions contemplated by the Merger Agreement, the Company has terminated all offerings of its securities pursuant to the Registration Statements and, in accordance with undertakings made by the Company in the Registration Statements to remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering, hereby removes and withdraws from registration all securities registered pursuant to the Registration Statements that remain unsold as of the date hereof. The Registration Statements are hereby amended, as appropriate, to reflect the deregistration of such securities.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-3 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Durham, State of North Carolina on the 22nd day of August 2024.

     

      Asensus Surgical, Inc.
         
      By: /s/         Shameze Rampertab
      Shameze Rampertab, Executive Vice President and Chief Financial Officer

     

    Pursuant to the Rule 478 of the Securities Act of 1933, as amended, no other person is required to sign this Post-Effective Amendment No. 1 to Registration Statement.

     

     
    Get the next $ASXC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ASXC

    DatePrice TargetRatingAnalyst
    11/16/2023Overweight → Neutral
    Cantor Fitzgerald
    9/8/2022$1.50Overweight
    Cantor Fitzgerald
    9/8/2022$1.50Buy
    Stifel
    More analyst ratings

    $ASXC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Starling William N Jr bought $5,078 worth of shares (18,134 units at $0.28) and sold $5,078 worth of shares (18,134 units at $0.28) (SEC Form 4)

    4 - ASENSUS SURGICAL, INC. (0000876378) (Issuer)

    12/18/23 6:26:08 PM ET
    $ASXC
    Medical/Dental Instruments
    Health Care

    $ASXC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Asensus Surgical Announces Closing of Acquisition by KARL STORZ

    RESEARCH TRIANGLE PARK, N.C. and TUTTLINGEN, Germany, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE:ASXC) ("Asensus Surgical" or "Asensus"), a global leader of innovative digital solutions for the operating room, today announced the closing of the merger (the "Merger") with the KARL STORZ Group ("KARL STORZ"). The transaction was completed following approval by the Asensus Surgical stockholders. Under the terms of the merger agreement, KARL STORZ Endoscopy-America, Inc., a wholly owned direct subsidiary of KARL STORZ, has acquired all outstanding shares of Asensus Surgical for $0.35 per share in cash. As a result of the acquisition, Asensus Surgical has become a sub

    8/22/24 8:58:30 AM ET
    $ASXC
    Medical/Dental Instruments
    Health Care

    Asensus Surgical, Inc. Reports Operating and Financial Results for the Second Quarter 2024

    RESEARCH TRIANGLE PARK, N.C., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE:ASXC), a global leader of innovative digital solutions for the operating room, announced its operating and financial results for the second quarter 2024. Recent Highlights Announced a definitive merger agreement (the "Merger Agreement") with KARL STORZ Endoscopy-America, Inc. ("KARL STORZ"), a wholly owned direct subsidiary of KARL STORZ SE & Co. KG, an independent, family-owned global medical technology company. Under the Merger Agreement, KARL STORZ will acquire all of the outstanding shares of Asensus Surgical for $0.35 per share in cash (the "Merger")Leading independent proxy advisory firms,

    8/13/24 4:05:00 PM ET
    $ASXC
    Medical/Dental Instruments
    Health Care

    Asensus Surgical, Inc. Schedules Second Quarter Financial and Operating Results Conference Call for August 13, 2024

    RESEARCH TRIANGLE PARK, N.C., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE:ASXC), a medical device company that is digitizing the interface between the surgeon and the patient, announced today that it plans to release 2024 second quarter financial and operating results after the market closes on Tuesday, August 13, 2024. The Company will host a conference call to discuss these results and the status of the proposed merger with KARL STORZ starting at 4:30 p.m. ET the same day. The call will be concurrently webcast. To listen to the conference call on your telephone, please dial 1-800-717-1738 for domesticcallers and 1-646-307-1865 for international callers, approximately

    8/8/24 6:50:00 AM ET
    $ASXC
    Medical/Dental Instruments
    Health Care

    $ASXC
    SEC Filings

    View All

    SEC Form 15-12G filed by Asensus Surgical Inc.

    15-12G - ASENSUS SURGICAL, INC. (0000876378) (Filer)

    9/3/24 7:00:04 AM ET
    $ASXC
    Medical/Dental Instruments
    Health Care

    SEC Form EFFECT filed by Asensus Surgical Inc.

    EFFECT - ASENSUS SURGICAL, INC. (0000876378) (Filer)

    8/27/24 12:15:07 AM ET
    $ASXC
    Medical/Dental Instruments
    Health Care

    SEC Form EFFECT filed by Asensus Surgical Inc.

    EFFECT - ASENSUS SURGICAL, INC. (0000876378) (Filer)

    8/27/24 12:15:04 AM ET
    $ASXC
    Medical/Dental Instruments
    Health Care

    $ASXC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Kwo Elizabeth returned 117,201 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - ASENSUS SURGICAL, INC. (0000876378) (Issuer)

    8/22/24 9:13:46 AM ET
    $ASXC
    Medical/Dental Instruments
    Health Care

    Director Hobert Kevin J returned 54,201 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - ASENSUS SURGICAL, INC. (0000876378) (Issuer)

    8/22/24 9:12:57 AM ET
    $ASXC
    Medical/Dental Instruments
    Health Care

    Director Pfenniger Richard C Jr returned 189,417 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - ASENSUS SURGICAL, INC. (0000876378) (Issuer)

    8/22/24 9:12:10 AM ET
    $ASXC
    Medical/Dental Instruments
    Health Care

    $ASXC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Asensus Surgical downgraded by Cantor Fitzgerald

    Cantor Fitzgerald downgraded Asensus Surgical from Overweight to Neutral

    11/16/23 7:11:26 AM ET
    $ASXC
    Medical/Dental Instruments
    Health Care

    Cantor Fitzgerald initiated coverage on Asensus Surgical with a new price target

    Cantor Fitzgerald initiated coverage of Asensus Surgical with a rating of Overweight and set a new price target of $1.50

    9/8/22 7:20:54 AM ET
    $ASXC
    Medical/Dental Instruments
    Health Care

    Stifel initiated coverage on Asensus Surgical with a new price target

    Stifel initiated coverage of Asensus Surgical with a rating of Buy and set a new price target of $1.50

    9/8/22 7:19:37 AM ET
    $ASXC
    Medical/Dental Instruments
    Health Care

    $ASXC
    Leadership Updates

    Live Leadership Updates

    View All

    Asensus Surgical Announces the Appointment of Two New Board Members

    Asensus Surgical, Inc. (NYSE:ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced the expansion of its Board of Directors, appointing two new board members, Elizabeth Kwo, MD and Kevin Hobert, effective immediately. "We are delighted to welcome two accomplished industry veterans to our Board of Directors, each of whom bring highly relevant and unique skills to the organization that complement our current leadership team in an impactful way," said Paul LaViolette, Chairman of the Board of Asensus Surgical. "Liz has a tremendous track record of bringing innovative healthcare t

    7/26/21 6:55:00 AM ET
    $ASXC
    Medical/Dental Instruments
    Health Care

    Cocrystal Pharma Announces the Passing of Chairman, CEO and Co-founder Dr. Gary Wilcox

    BOTHELL, Wash., May 28, 2021 (GLOBE NEWSWIRE) -- With great sadness, Cocrystal Pharma, Inc. (NASDAQ:COCP), ("Cocrystal" or the "Company") announces that Gary Wilcox, Ph.D., Chairman, CEO and co-founder, suddenly passed away Wednesday, May 26 at the age of 74. The Board of Directors and staff of Cocrystal extend their deepest condolences to the Wilcox family and express their gratitude for Gary's contributions to Cocrystal and to human health. The Cocrystal Board of Directors has designated Sam Lee, Ph.D., President, and James Martin, CFO, to share the CEO responsibilities while seeking a successor for the position. Roger Kornberg, Ph.D., Cocrystal co-founder, Chief Scientist, Director and

    5/28/21 8:00:00 AM ET
    $OPK
    $ASXC
    $GPX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments
    Other Consumer Services

    $ASXC
    Financials

    Live finance-specific insights

    View All

    Asensus Surgical, Inc. Schedules Second Quarter Financial and Operating Results Conference Call for August 13, 2024

    RESEARCH TRIANGLE PARK, N.C., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE:ASXC), a medical device company that is digitizing the interface between the surgeon and the patient, announced today that it plans to release 2024 second quarter financial and operating results after the market closes on Tuesday, August 13, 2024. The Company will host a conference call to discuss these results and the status of the proposed merger with KARL STORZ starting at 4:30 p.m. ET the same day. The call will be concurrently webcast. To listen to the conference call on your telephone, please dial 1-800-717-1738 for domesticcallers and 1-646-307-1865 for international callers, approximately

    8/8/24 6:50:00 AM ET
    $ASXC
    Medical/Dental Instruments
    Health Care

    Asensus Surgical, Inc. Schedules First Quarter Financial and Operating Results Conference Call for May 14, 2024

    RESEARCH TRIANGLE PARK, N.C., May 07, 2024 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE:ASXC), a medical device company that is digitizing the interface between the surgeon and the patient, announced today that it plans to release 2024 first quarter financial and operating results after the market closes on Tuesday, May 14, 2024. The Company will host a conference call to discuss these results starting at 4:30 p.m. ET the same day. The call will be concurrently webcast. To listen to the conference call on your telephone, please dial 1-888-886-7786 for domestic callers and 416-764-8658 for international callers, approximately ten minutes prior to the start time. To access the live audi

    5/7/24 6:55:00 AM ET
    $ASXC
    Medical/Dental Instruments
    Health Care

    Asensus Surgical, Inc. Schedules Fourth Quarter and Full Year 2023 Financial and Operating Results Conference Call for March 21, 2024

    RESEARCH TRIANGLE PARK, N.C., March 15, 2024 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE:ASXC), a medical device company that is digitizing the interface between the surgeon and the patient, announced today that it plans to release fourth quarter and full year 2023 financial and operating results after the market closes on Thursday, March 21, 2024. The Company will host a conference call to discuss these results starting at 4:30 p.m. ET the same day. The call will be concurrently webcast. To listen to the conference call on your telephone, please dial 1-888-886-7786 for domestic callers and 416-764-8658 for international callers, approximately ten minutes prior to the start time. To

    3/15/24 6:55:00 AM ET
    $ASXC
    Medical/Dental Instruments
    Health Care

    $ASXC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Asensus Surgical Inc.

    SC 13G - ASENSUS SURGICAL, INC. (0000876378) (Subject)

    7/15/24 5:33:42 PM ET
    $ASXC
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Asensus Surgical Inc. (Amendment)

    SC 13G/A - ASENSUS SURGICAL, INC. (0000876378) (Subject)

    1/20/23 9:38:51 AM ET
    $ASXC
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Asensus Surgical Inc.

    SC 13G - ASENSUS SURGICAL, INC. (0000876378) (Subject)

    2/10/22 12:45:15 PM ET
    $ASXC
    Medical/Dental Instruments
    Health Care